Peter Wirth

Peter Wirth has an estimated net worth of $34.4 Million. This is based on reported shares across multiple companies, which include GENZYME CORP, Zai Lab Ltd, Forma Therapeutics Holdings, Inc.,, Syros Pharmaceuticals, Inc., SYNAGEVA BIOPHARMA CORP, and EPIX MEDICAL INC.

2022 was Peter Wirth's most active year for acquiring shares with 6 total transactions. Peter Wirth's most active month to acquire stocks was the month of May. 2011 was Peter Wirth's most active year for disposing of shares, totalling 16 transactions. Peter Wirth's most active month to dispose stocks was the month of March. 2009 saw Peter Wirth paying a total of $6,835,379.20 for 289,180 shares, this is the most they've acquired in one year. In 2009 Peter Wirth cashed out on 464,360 shares for a total of $15,439,970.00, their largest year based on trade value.